Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial

Authors :: Sénat, Marie-Victoire
Affres, Helene
Letourneau, Alexandra
Coustols-Valat, Magali
Cazaubiel, Marie
Legardeur, Helene
Jacquier, Julie Fort
Bourcigaux, Nathalie
Simon, Emmanuel
Rod, Anne
Héron, Isabelle
Castera, Virginie
Sentilhes, Loic
Bretelle, Florence
Rolland, Catherine
Morin, Mathieu
Deruelle, Philippe
De Carne, Celine
Maillot, François
Beucher, Gael
Verspyck, Eric
Desbriere, Raoul
Laboureau, Sandrine
Mitanchez, Delphine
Bouyer, Jean
Source :: Obstetrical and Gynecological Survey; September 2018, Vol. 73 Issue: 9 p511-513, 3p
Publication Year :: 2018
Abstract: (Abstracted from JAMA2018;319(17):1773–1780)Gestational diabetes continues to increase nationally and globally. The American Diabetes Association currently recommends insulin, the only Food and Drug Administration–approved pharmacologic agent, as first-line treatment for women with gestational diabetes mellitus requiring medications.

Full Text Access

Tools